Healios, Athersys Confident Despite Missed Japan Stroke Endpoint
Investors Much Less Upbeat
A missed primary endpoint in new top-line results from a Japanese trial with the stem cell therapy for stroke MultiStem hits Athersys and Japanese partner hard, casting a shadow over ongoing studies.
